Synthetic Turf Could Cause Cancer in Athletes
the Cancer Therapy Advisor take:
Amy Griffin, a 27-year soccer coach, began to notice an uptick in cancer among players and is concerned that the increase in use of artificial turf may be an underlying cause. Griffin began her crusade in 2009 and has compiled a list of 50 American soccer players, mostly goal keepers, who have been diagnosed with cancer.
Turf fields, which use crumb rubber to mimic natural soil, are popular because they are lower maintenance and provide a consistent playing field for athletes without watering —they are also seen as environmentally friendly because they recycle old tires into a new resource.
Griffin is concerned that the use of potentially carcinogenic material is a risk factor, especially for goalkeepers who often have open wounds while in close contact with the turf material. At this point, however, Griffin’s case against synthetic turf is anecdotal—there simply isn’t enough evidence to support her claims about relationship between turf and cancer incidence.
Makers of the turf field argue that academic, federal, and state government organizations has never found a link between synthetic turf and cancer but that they are willing to support continued research where appropriate. As of now, the EPA is committed to conducting research on a field-by-field basis to ensure that field materials are safe and players are not at risk.
The increase in use of artificial turf may be an underlying cause of cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Opinion: Understanding the FDA's Take on Cannabidiol
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer